Liver Diseases  >>  brivanib alaninate (BMS-582664)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brivanib alaninate (BMS-582664) / ZAI Lab
NCT00437424: A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Completed
1
24
US, Europe
Brivanib, BMS-582664
Bristol-Myers Squibb
Carcinoma, Hepatocellular
06/10
06/10
NCT01540461: Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Completed
1
17
RoW
Brivanib, BMS-582664
Bristol-Myers Squibb
Hepatocellular Carcinoma
11/13
11/13

Download Options